Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

armodafinil

50 mg/day armodafinil

DRUG

armodafinil

100 mg/day armodafinil

DRUG

armodafinil

200 mg/day armodafinil

DRUG

placebo

placebo

Trial Locations (12)

27705

Duke Department of Psychiatry - DUMC, Durham

30308

Atlanta Center for Clinical Research, Atlanta

45408

Midwest Clinical Research Center, Dayton

60612

Rush University Medical Center, Chicago

63108

Washington University School of Medicine, St Louis

75062

University Hills Clinical Research, Irving

90660

CNRI-Los Angeles, LLC, Pico Rivera

90723

California Clinical Trials, Paramount

91950

Synergy Clinical Research, National City

92126

CNRI-San Diego, San Diego

92845

Collaborative NeuroScience Network, Garden Grove

06519

Yale University School of Medicine, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY